Oruka Therapeutics, Inc.
91.50USD
-2.8100 (-2.98%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.62▼ | $-0.51 | 1 | 6 |
| Next quarter | $-0.66▼ | $-0.53 | 1 | 7 |
| Current year | $-2.37▼ | $-2.04 | 1 | 7 |
| Next year | $-2.86▼ | $-2.46 | 3 | 5 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.5 | $-0.55 | -0.05 (-9.9%) |
| 2026-03-31 | $-0.54 | $-0.48 | +0.06 (+10.6%) |
| 2025-12-31 | $-0.62 | $-0.45 | +0.17 (+26.9%) |
| 2025-09-30 | $-0.52 | $-0.55 | -0.03 (-5.0%) |
56 ratings from 15 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 3, 2026 |
| Guggenheim | Reiterated | Buy | $200 | Aug 11, 2026 |
| Wedbush | Reiterated | Outperform | $165 | Aug 11, 2026 |
| BTIG | Reiterated | Buy | $151 | Aug 11, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Aug 3, 2026 |
| BTIG | Reiterated | Buy | $151 | Jul 13, 2026 |
| UBS | Maintained | Buy | $100 $130 | Jul 1, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | Jun 23, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $120 | May 18, 2026 |
| BTIG | Reiterated | Buy | $151 | May 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75 $120 | Apr 29, 2026 |
| UBS | Maintained | Buy | $75 $100 | Apr 28, 2026 |
| Barclays | Maintained | Overweight | $78 $160 | Apr 28, 2026 |
| BTIG | Maintained | Buy | $78 $151 | Apr 27, 2026 |
| Wedbush | Maintained | Outperform | $45 $85 | Apr 15, 2026 |
| Guggenheim | Reiterated | Buy | $125 | Apr 13, 2026 |
| BTIG | Maintained | Buy | $73 $78 | Apr 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40 $70 | Apr 13, 2026 |
| Guggenheim | Reiterated | Buy | $125 | Apr 9, 2026 |
| Barclays | Maintained | Overweight | $50 $78 | Apr 7, 2026 |
| UBS | Maintained | Buy | $50 $75 | Apr 6, 2026 |
| Guggenheim | Maintained | Buy | $60 $125 | Apr 6, 2026 |
| Leerink Partners | Maintained | Outperform | $58 $86 | Mar 16, 2026 |
| Barclays | Maintained | Overweight | $48 $50 | Mar 13, 2026 |
| BTIG | Reiterated | Buy | $73 | Mar 13, 2026 |
68 filings from 11 insiders · 18 buy / 26 sell over 6m
Officers and directors of ORKA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sandler Laura LeeOfficer, Chief Operating Officer | ExerciseEmployee Warrant (right to buy) | 5.0k | — | — | Sep 1, 2026 |
| Sandler Laura LeeOfficer, Chief Operating Officer | Sell | 4.0k | $92.01 | $368k | Sep 1, 2026 |
| Sandler Laura LeeOfficer, Chief Operating Officer | Sell | 1.0k | $91.05 | $91k | Sep 1, 2026 |
| Sandler Laura LeeOfficer, Chief Operating Officer | Exercise | 5.0k | $7.80 | $39k | Sep 1, 2026 |
| Klein Lawrence OttoDirector; Officer, Chief Executive Officer | ExerciseEmployee Warrant (right to buy) | 75.0k | — | — | Sep 1, 2026 |
| Klein Lawrence OttoDirector; Officer, Chief Executive Officer | Sell | 4.8k | $92.44 | $444k | Sep 1, 2026 |
| Klein Lawrence OttoDirector; Officer, Chief Executive Officer | Sell | 63.6k | $91.90 | $5.84M | Sep 1, 2026 |
| Klein Lawrence OttoDirector; Officer, Chief Executive Officer | Sell | 6.6k | $90.79 | $600k | Sep 1, 2026 |
| Klein Lawrence OttoDirector; Officer, Chief Executive Officer | Exercise | 75.0k | $7.80 | $585k | Sep 1, 2026 |
| EDWARDS LARRY TODDOfficer | Grant | 100.0k | — | — | Aug 24, 2026 |
| GONCALVES JOANAOfficer | Sell | 7.0k | $109.65 | $783k | Aug 17, 2026 |
| GONCALVES JOANAOfficer | Exercise | 7.0k | $6.84 | $51k | Aug 17, 2026 |
| QUINLAN PAUL TGeneral Counsel | Sell | 52.0k | $106.05 | $5.64M | Aug 14, 2026 |
| QUINLAN PAUL TGeneral Counsel | Exercise | 52.0k | $7.80 | $603k | Aug 14, 2026 |
| AGARWAL ARJUNOfficer | Sell | 10.0k | $104.67 | $1.07M | Aug 13, 2026 |
| AGARWAL ARJUNOfficer | Exercise | 10.0k | $12.50 | $157k | Aug 13, 2026 |
| GONCALVES JOANAOfficer | Sell | 7.0k | $84.36 | $604k | Jul 15, 2026 |
| GONCALVES JOANAOfficer | Exercise | 7.0k | $6.84 | $51k | Jul 15, 2026 |
| AGARWAL ARJUNOfficer | Sell | 10.0k | $83.07 | $846k | Jul 13, 2026 |
| AGARWAL ARJUNOfficer | Exercise | 10.0k | $12.50 | $157k | Jul 13, 2026 |
No analyst notes on ORKA yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 1 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 2 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |
| 3 mo ago | 2 | 11 | 0 | 0 | 0 | Buy1.85 |